Pharma

Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer

  • by

Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI… Read More »Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

  • by

Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China,… Read More »Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC

  • by

Shots: The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in patients with LA or mNSCLC after prior TKI therapy NKMax will sponsor the study while Merck KGaA will supply cetuximab… Read More »Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC

Sanofi Collaborates with C4XD for an Oral Therapy to Treat Inflammatory Diseases

  • by

Shots: Sanofi has signed an exclusive worldwide licensing agreement with C4XD worth up to $492.94M million, for C4XD’s oral pre-clinical IL-17A inhibitor program C4XD to receive $8.33M up front and is eligible to receive up to $484.60M as development, regulatory and commercial milestones including $13.09M… Read More »Sanofi Collaborates with C4XD for an Oral Therapy to Treat Inflammatory Diseases

KOL Mindset Mapping

  • by

Once you have successfully identified, mapped, and begun engagement with your KOLs, the next step in the KOL management cycle should be to assess, benchmark, and track KOL mindset.   A mindset mapping study enables you to gauge KOL views on key therapeutic and management… Read More »KOL Mindset Mapping

How eConsent empowers more participant engagement in clinical trials

  • by

Creating the simplest process for informed consent benefits the potential participant by allowing them the time and resources to understand fully what they are consenting to. Through eConsent processes, research also opens the door to a more diverse population to engage in trials.

Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

  • by

Shots: The companies initiate the clinical trial of A2a receptor antagonist, co-developed by Exscientia and Evotec utilizing Exscientia’s AI-design platform, Centaur Chemist Exscientia will lead the clinical development phase of the molecule and Evotec retains co-ownership rights throughout clinical development The A2a receptor is currently… Read More »Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug

How a Virtual Care Mindset Leads to Greater Patient Acceptance and Sustainable Telehealth Growth

  • by

Sandeep Pulim, MD, Chief Medical Officer at Bluestream Health There’s no question that the demand for telehealth and virtual care has grown exponentially over the last twelve months. With that growth has come a fundamental shift in the attitude toward virtual care. No longer do… Read More »How a Virtual Care Mindset Leads to Greater Patient Acceptance and Sustainable Telehealth Growth

3rd Cell Engager Summit

  • by

With that in mind, the 3rd Cell Engager Summit (June 30 – July 1) is the only industry-led meeting focused on developing multi-specific cell engaging therapies in solid tumor indications, and accelerating early discovery innovation into the clinic. With over 32 world-class speakers set to share their ground-breaking insights, this… Read More »3rd Cell Engager Summit

Next-Generation Cloud Storage: Enabling Collaboration & Analytics for Pharma Research

  • by

Russ Kennedy, Chief Product Officer, Nasuni Pharmaceutical companies today are distributed, global organizations, with research centers, manufacturing facilities, and regulatory management hubs spread all over the globe. To develop new treatments and bring them to market, all of these different functions need to collaborate more… Read More »Next-Generation Cloud Storage: Enabling Collaboration & Analytics for Pharma Research

Bristol Myers Squibb SVP Ho Sung Cho highlights legacy and ongoing research in protein degradation  [Sponsored]

  • by

Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a recent MedCity Pivot Podcast, he also shared insights on his approach to drug discovery, perspectives on dealing with failure, and… Read More »Bristol Myers Squibb SVP Ho Sung Cho highlights legacy and ongoing research in protein degradation  [Sponsored]

AstraZeneca updates Covid-19 vaccine data, now showing 76% efficacy

  • by

AstraZeneca’s latest efficacy data for its Covid-19 vaccine are down slightly from the 79% it previously reported. The most recent data will form the basis of an application for emergency use authorization, which the company still expects to file with the FDA in coming weeks.

Mapping Voices

  • by

Instead of thinking about mapping KOLs and stakeholders, consider thinking about mapping all the “voices” in your disease ecosystem.   A voice that impacts, influences, or inspires the success of your brand could encompass everything from traditional KOLs to nursing pacesetters, from long-established patient groups… Read More »Mapping Voices

AstraZeneca’s Covid-19 vaccine data may have ‘outdated information,’ NIH cautions

  • by

Federal health authorities say safety observers are concerned AstraZeneca did not release complete information about the efficacy of its Covid-18 vaccine. The company responded by saying its data were from a pre-specified analysis and it will provide the most up to date efficacy data within… Read More »AstraZeneca’s Covid-19 vaccine data may have ‘outdated information,’ NIH cautions

Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

  • by

Shots: Boston will lead the development of selected programs through PoC. GSK gets an option to reacquire each program under pre-agreed terms for development and WW commercialization, after completion of POC studies If GSK exercises its repurchase option, Boston to receive a one-time payment and… Read More »Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

  • by

Shots: Boston will lead the development of selected programs through PoC. GSK gets an option to reacquire each program under pre-agreed terms for development and WW commercialization, after completion of POC studies If GSK exercises its repurchase option, Boston to receive a one-time payment and… Read More »Boston Signs Out-License and Option Agreement with GSK to Advance Two Programs for Oncology and CNS Disorders

Gilead Collaborates with Merck to Jointly Develop and Commercialize Lenacapavir + Islatravir for HIV

  • by

Shots: The companies will co-develop & co-commercialize the combination of Gilead’s Lenacapavir and Merck’s Islatravir in long-acting oral & injectable formulations for HIV. Gilead & Merck will share global development & commercialization costs (60%/40%) respectively For oral products, Gilead will lead commercialization in the US… Read More »Gilead Collaborates with Merck to Jointly Develop and Commercialize Lenacapavir + Islatravir for HIV

BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma

  • by

Shots: The P-III TiNivo-2 study involves assessing Fotivda (1.34 mg/qd for 21days followed by 7days off treatment) + Opdivo (480 mg, q4w) in ~326 patients in a ratio (1:1) with advanced r/r metastatic RCC following prior immunotherapy exposure The study plans to enroll patients across… Read More »BMS Collaborates with Aveo to Evaluate Opdivo (nivolumab) + Fotivda (tivozanib) in P-III Study for Relapsed Renal Cell Carcinoma

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

  • by

Shots: Ovid to receive $196M as up front and an additional $660M as development, regulatory and sales milestones along with royalties and up to 20% on sales of soticlestat. The agreement is expected to close by end of March 2021 Takeda to get all global… Read More »Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

  • by

Shots: On Feb 12, 2021, the US FDA has approved Cosela to decrease the incidence of CT induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC The launch is supported by the “One Patient Support Program” which is… Read More »G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

  • by

Shots: AstraZeneca to get exclusive promotion rights for toripalimab in mainland China for the urothelial carcinoma indications and all indications in non-core areas Junshi will continue responsible for the promotion of other approved indications and to be approved excluding urothelial carcinoma in core areas The… Read More »AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant

  • by

Shots: Debiopharm to receive $226M up front, ~$853.7M as regulatory and commercial milestones along with royalties. The transaction is expected to close in early Q2’21 Merck KGaA get an exclusive right to develop and commercialize xevinapant globally, including in the US and will co-fund the… Read More »Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant

Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma

  • by

Shots: LYSA-LYSARC to conduct a P-II study to evaluate the safety and efficacy of valemetostat in six cohorts of patients with r/r B-cell lymphoma. The study will include ~140 patients at 22 sites in France and Belgium and is anticipated to be initiated in 2021… Read More »Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma

Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

  • by

Shots: Following the completion of a P-I program, the company plans to initiate P- II studies to evaluate ITI-1284 ODT-SL for the treatment of behavioral disturbances in dementia, dementia-related psychosis and certain depressive disorders in the elderly The P-I single and multiple ascending dose studies… Read More »Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

Merck KGaA Signs an Exclusive Worldwide License Agreement with Day One for Pimasertib and MSC2015103B

  • by

Shots: Merck KGaA to receive up front, additional regulatory, approval, and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of MEK inhibitors Day One plans to initiate a… Read More »Merck KGaA Signs an Exclusive Worldwide License Agreement with Day One for Pimasertib and MSC2015103B

Graviton Signs an Exclusive Worldwide License Agreement with Beijing Tide for TDI01

  • by

Shots: Beijing Tide to receive up to $517.5M including up front, development, regulatory and sales milestone along with royalties and an option for a revenue-sharing arrangement for certain developed products Graviton to get exclusive development and commercialization rights for TDI01 in all territories (Ex- China)… Read More »Graviton Signs an Exclusive Worldwide License Agreement with Beijing Tide for TDI01

RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204

  • by

Shots: The companies signed an agreement to manufacture movantik for opioid-induced constipation and RHB-204, currently in a P-III US study as a stand-alone 1L treatment for pulmonary NTM disease Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the US specifically… Read More »RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204

Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases

  • by

Shots: Rigel to receive $125M up front and is also eligible to receive ~$835M as development, regulatory and commercial milestones as well as royalties, which will vary depending upon Rigel’s clinical development investment Lilly to get an exclusive WW license to Rigel’s RIPK1 inhibitors, including… Read More »Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases

Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology

  • by

Shots: Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies Onward get the right to pursue development, manufacture & commercialize first-in-class bispecific Ab. The companies will jointly develop the Ab during the preclinical and early… Read More »Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology

Evotec Collaborates with Related Sciences for Drug Discovery and Development

  • by

Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a multitude of therapeutic approaches with IND filings over a multi-year period. The partnership will combine… Read More »Evotec Collaborates with Related Sciences for Drug Discovery and Development

Pfizer Signs a License and Research Agreement with Imcyse to Develop Imotopes for Rheumatoid Arthritis

  • by

Shots: Imcyse to receive up front, ~$180M as milestones along with royalties. Pfizer to purchase an equity stake in Imcyse Initially, the companies will collaborate to develop existing lead candidates and further optimize potential molecules. Later, Pfizer will lead clinical development and commercialization activities for… Read More »Pfizer Signs a License and Research Agreement with Imcyse to Develop Imotopes for Rheumatoid Arthritis

Genentech Signs an Exclusive License Agreement with X-Chem to Discover Oncology Targets

  • by

Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will lead further development and commercialization of any potential new therapies and retain exclusive rights to… Read More »Genentech Signs an Exclusive License Agreement with X-Chem to Discover Oncology Targets

ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Neuvogen for CD8 ImmunoPET Technology

  • by

Shots: ImaginAb to receive license fees and other contingent payments and will partner with Neuvogen to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents in their clinical trials of therapeutic vaccines ImaginAb will provide technical, clinical & regulatory support to Neuvogen. ImaginAb’s PET imaging… Read More »ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Neuvogen for CD8 ImmunoPET Technology

Prescient Healthcare Group to Partner with Bridgepoint Development Capital

  • by

The partnership will further enhance the depth, breadth and value of services for Prescient’s pharmaceutical and biotech clients. LONDON, January 21, 2021: Prescient Healthcare Group (Prescient), a global product strategy advisory firm serving the pharmaceutical and biotech industries, announced today that Bridgepoint Development Capital, part… Read More »Prescient Healthcare Group to Partner with Bridgepoint Development Capital

Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders

  • by

Shots: Evoq to receive ~$240M up front & milestones along with royalties on the sales of therapies emerges from the collaboration The companies collaborated on preclinical development, while Amgen will be responsible for clinical development and commercialization The collaboration will bolster Amgen’s autoimmune offerings as… Read More »Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

  • by

Shots: The companies plan to initiate a P-II study assessing selgantolimod + VIR-2218 in treatment-experienced and treatment-naïve people living with HBV. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy The 1EPs of the study will be the proportion of patients… Read More »Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

BMS Collaborates with ArsenalBio to Advance Next-Generation T cell Therapies for Solid Tumors

  • by

Shots: ArsenalBio to receive $70M as up front and is eligible to receive additional payments associated with collaboration expansion, regulatory & commercial milestones along with royalties on sales of approved products ArsenalBio will be responsible for discovering and building preclinical candidates against multiple targets while… Read More »BMS Collaborates with ArsenalBio to Advance Next-Generation T cell Therapies for Solid Tumors

Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases

  • by

Shots: Chi-Med to receive ~$95M and ~$135M as development & commercial milestones along with royalties on commercialization of each drug candidates. Inmagene to get an exclusive option for four drug candidates solely for immunological diseases If Inmagene exercises the option, it will get the right… Read More »Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

  • by

Shots: Dewpoint to receive up front payment and up to $239M as research, development & commercial milestones along with royalties on sales of the therapies The companies collaborated for the development of therapies to treat DM1 The companies will collaborate their expertise to advance the… Read More »Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Evotec Receives Milestones in its Neurodegeneration Collaboration with BMS

  • by

Shots: Evotec has received $6M as milestones under its iPSC-based neuroscience alliance with BMS. The milestones follow BMS’ decision to add another drug discovery project to the partnership’s portfolio In 2016, the companies collaborated to identify disease-modifying treatments for neurodegenerative diseases The partnership b/w both… Read More »Evotec Receives Milestones in its Neurodegeneration Collaboration with BMS

Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

  • by

Shots: Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of… Read More »Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021

  • by

As we close out the year, we asked several healthcare executives to share their predictions and trends for 2021. Kimberly Powell, Vice President & General Manager, NVIDIA Healthcare Federated Learning: The clinical community will increase their use of federated learning approaches to build robust AI models across various… Read More »30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021

Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases

  • by

Shots: Skyhawk to receive $40M as upfront and is eligible to receive up to $2.2B as milestones along with royalties on sales. Vertex to get an option to exclusively license WW IP rights to candidates discovered and developed under the collaboration directed at serious diseases… Read More »Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases

Myovant Signs Agreement with Pfizer to Develop and Commercialize Relugolix in Oncology and Women’s Health

  • by

Shots: Myovant & Pfizer will jointly develop & commercialize ORGOVYX (relugolix) in advanced prostate cancer & if approved, relugolix combination tablet in women’s health in the US & Canada. Myovant will receive ~$4.2B including $650M upfront, $200M in regulatory milestones for FDA approvals for relugolix… Read More »Myovant Signs Agreement with Pfizer to Develop and Commercialize Relugolix in Oncology and Women’s Health

Aurobindo Pharma Sign Agreement with COVAXX to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF

  • by

Shots: In the agreement, Aurobindo has obtained the exclusive rights to develop, manufacture & sell COVAXX’s UB-612 vaccine in India & UNICEF & also non-exclusive rights in other selected emerging & developing markets UB-612 is presently being assessed in P-I will be manufactured by Aurobindo… Read More »Aurobindo Pharma Sign Agreement with COVAXX to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF

GSK Signs a License Agreement with Sosei Heptares Targeting Immune Disorders of the Digestive System

  • by

Shots: Sosei Heptares to receive $44M as upfront, near-term development milestones, and funding and is eligible to receive $437M as development, regulatory, and commercialization along with royalties on sales of products resulting from the collaboration GSK gets the global rights to a Sosie Heptares’ portfolio… Read More »GSK Signs a License Agreement with Sosei Heptares Targeting Immune Disorders of the Digestive System

FDA gives nod to Moderna vaccine for Covid-19

  • by

The company’s vaccine is the second approved for emergency use by the FDA. It is expected to pose fewer logistical challenges than the first, which was developed by Pfizer and BioNTech.

GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813

  • by

Shots: Surface Oncology to receive ~$85 M upfront and ~$730 M as milestones along with royalties on net sales of SRF813 GSK to get an exclusive right to develop and commercialize Surface Oncology’s preclinical program, SRF813 SRF813 is an IgG1 Ab targeting PVRIG (also k/a… Read More »GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813

Genentech Signs a Worldwide License Agreement with Relay Therapeutics to Develop and Commercialize RLY-1971

  • by

Shots: Relay to receive $75M as upfront, $25M in additional near-term payments, and has the right to opt for 50/50 profit/cost-sharing on RLY-1971 in the US. If Relay exercises the option, it will be eligible to receive 50% profits on US sales & ~$410M as… Read More »Genentech Signs a Worldwide License Agreement with Relay Therapeutics to Develop and Commercialize RLY-1971

Survey Finds Telehealth Is Convenient Alternative, Will Likely Continue Beyond the Pandemic

  • by

A new Health Union survey reveals that people with chronic conditions feel that telehealth, despite its convenience and increased use throughout the COVID-19 pandemic, is generally less preferable than in-person visits, but can still serve as an occasionally suitable alternative. The survey is the fifth… Read More »Survey Finds Telehealth Is Convenient Alternative, Will Likely Continue Beyond the Pandemic

Bayer Signs an Exclusive Worldwide License Agreement with Atara for Mesothelin-Targeted CAR T-cell Therapies to Treat Solid Tumors

  • by

Shots: Atara to receive $60M upfront and ~$610M as development, regulatory & commercialization milestones + tiered royalties on net sales. The collaboration focuses on off-the-shelf T-cell immunotherapy ATA3271 and ATA2271 Atara will lead to IND and process development for ATA3271 and will continue to be… Read More »Bayer Signs an Exclusive Worldwide License Agreement with Atara for Mesothelin-Targeted CAR T-cell Therapies to Treat Solid Tumors

PRISYM 360 Achieves SAP® Certification as Integrated with Cloud Solutions from SAP

  • by

PRISYM 360 Achieves SAP® Certification as Integrated with Cloud Solutions from SAP The latest version of the PRISYM 360 intelligent data import connector now has SAP-certified integration using SAP Cloud Platform Integration Suite Wokingham, United Kingdom — 7 December 2020 — PRISYM ID, a leading provider… Read More »PRISYM 360 Achieves SAP® Certification as Integrated with Cloud Solutions from SAP

4th Antigen Specific Immune Tolerance Summit

  • by

The 4th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to… Read More »4th Antigen Specific Immune Tolerance Summit

AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

  • by

Shots: Frontier to receive ~$100M including $55M upfront and remaining as milestones within the first 12mos. of collaboration and is eligible for development & commercial milestone that could exceed $1B, along with royalties on commercialized products Following the completion of pre-clinical development, AbbVie will lead… Read More »AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

CVS to distribute newly authorized antibody therapy

  • by

CVS Health’s infusion business will participate in a pilot to administer a recently authorized monoclonal antibody treatment to prevent patients from getting seriously ill with Covid-19. But data about the treatment, bamlanivimab, is mixed, and supply is limited.

Eisai Sign a Research Agreement with Wren Therapeutics to Discover Potential Treatment for Synucleinopathies

  • by

Shots: The companies entered into an exclusive research agreement for the discovery of novel small molecules targeting α-synuclein for the potential treatment of synucleinopathies including PD and dementia with Lewy bodies The collaboration will use Wren’s network kinetics drug discovery platform along with Eisai’s experience… Read More »Eisai Sign a Research Agreement with Wren Therapeutics to Discover Potential Treatment for Synucleinopathies

Shionogi and Nagasaki University Collaborate with the Kitasato Institute for Antimalarial Drugs

  • by

Shots: Kitasato & Shionogi-Nagasaki will collaborate on the R&D of the new antimalarial natural products discovered by Ōmura Satoshi Memorial Institute for the antimalarial drugs The collaboration accelerates the research for antimalarial drugs & vaccines by fostering an open innovation platform merging the strengths of… Read More »Shionogi and Nagasaki University Collaborate with the Kitasato Institute for Antimalarial Drugs

PostEra Collaborates with NeuroLucent to Identify Therapies for Alzheimer’s Disease

  • by

Shots: NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate PostEra will use its ML technology to optimize NeuroLucent’s lead compounds through a series of design make test cycles that… Read More »PostEra Collaborates with NeuroLucent to Identify Therapies for Alzheimer’s Disease

Evotec Collaborates with Rappta Therapeutics to Focus on Oncology Target

  • by

Shots: Evotec to receive research funding & is eligible for milestones. Evotec will support Rappta’s program of developing small molecule activators of the enzyme PP2A The collaboration leverages Evotec’s integrated platform for drug discovery and development and its oncology expertise coupled with state-of-the-art technologies PP2A… Read More »Evotec Collaborates with Rappta Therapeutics to Focus on Oncology Target

Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas

  • by

Shots: Schrödinger to receive $55M upfront and is eligible to receive $2.7B as preclinical, development, regulatory & commercial milestones along with royalties on sales of each product commercialized by BMS Schrödinger to grant BMS exclusive WW rights to develop & commercialize the development candidates emerges… Read More »Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas

Pfizer And LianBio Collaborate to Expand the Development of Novel Therapeutics in Greater China

  • by

Shots: Pfizer & LianBio collaborate to focus at developing & commercializing transformative therapies in Greater China. Both the companies will leverage their clinical development, regulatory and commercial expertise Pfizer will contribute ~$70M of non-dilutive capital toward in-licensing & co-development. At LianBio’s discretion, products will be… Read More »Pfizer And LianBio Collaborate to Expand the Development of Novel Therapeutics in Greater China

7 Best Practices for Third-Party Risk Management in the Pharmaceutical Industry

  • by

Dr. Aleksandr Yampolskiy, CEO of SecurityScorecard, The globalization of the pharmaceutical industry has forced pharma companies to outsource, increasing their reliance on third-party vendors and suppliers. As this supply chain grows in complexity, companies find themselves grappling with a growing amount of cyber risk.  A… Read More »7 Best Practices for Third-Party Risk Management in the Pharmaceutical Industry

TGFB for Immuno-Oncology Drug Development Summit

  • by

Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development? Recent scientific, clinical breakthroughs and high-profile industry deals have reignited the race to find the next blockbuster TGF-ß inhibitor for immuno-oncology applications. As such, the TGFß for Immuno-Oncology Drug Development Summit (January 26-28) is the… Read More »TGFB for Immuno-Oncology Drug Development Summit

Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases

  • by

Shots: Lead Pharma receives ~$11.86M upfront and is eligible to receive funding and ~$307.9 as research, development, regulatory and commercial milestones along with royalties on sales of small molecules The companies will collaborate in research activities up to the selection of a pre-clinical candidate after… Read More »Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases

Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer

  • by

Shots: Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study The 1st part will evaluate the safety of the combination regimen while the 2nd part will assess the safety, tolerability, and… Read More »Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer

Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies

  • by

Shots: Seed Therapeutics to receive $10M upfront, $10M equity investment, ~$780M as pre/clinical development, regulatory & commercial milestones along with royalties on net sales of products that emerges from the collaboration Seed utilizes molecular glue protein degradation technology to develop potential new therapies The agreement… Read More »Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies

5 Things Patient Advocates Want Pharma and the Healthcare Industry to Know

  • by

The COVID-19 pandemic has presented many obstacles, yet the healthcare industry continues to march forward to meet the needs of patients. With physical distancing, new office protocols and the widespread use of telehealth, the patient experience is changing–particularly for people living with chronic conditions, who… Read More »5 Things Patient Advocates Want Pharma and the Healthcare Industry to Know

Merck and Transcenta Collaborate to Implement Continuous Manufacturing for Protein Therapeutics

  • by

Shots: The companies will co-develop a first-of-its-kind, single-use flow-through polishing system for GMP operation. The collaboration expected to accelerate affordable access to therapeutics for patients in China and globally The agreement will initially focus on developing and designing the process technologies and automation while later… Read More »Merck and Transcenta Collaborate to Implement Continuous Manufacturing for Protein Therapeutics

AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer

  • by

Shots: Fusion to receive up front, as well as development milestones and other payments. The companies will jointly discover, develop, and have an option to co-commercialize novel TATs in the US while AstraZeneca will lead commercialization in the ROW with equal profit & loss sharing… Read More »AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer

Thermo Fisher Expands its Direct-to-Patient Service Offerings

  • by

Shots: The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020… Read More »Thermo Fisher Expands its Direct-to-Patient Service Offerings

Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder

  • by

Shots: SpringWorks to receive $35M as upfront and $ 375M as clinical, regulatory, and commercial milestones and is eligible to receive royalties on future net sales of PF-04457845. Jazz to get an exclusive license of all assets relating to the FAAH inhibitor program including PF-04457845… Read More »Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder

Bayer paying up to $4B for gene therapy pioneer AskBio

  • by

The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson’s and congestive heart failure.

Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

  • by

Shots: The companies collaborate for fast-track development of DNP-019 against COVID-19 The collaboration will expand Samsung’s CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing Samsung has introduced its proprietary cell-line… Read More »Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China

  • by

Shots: ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW The collaboration accelerates the development path… Read More »ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease

  • by

Shots: Arrowhead to receive ~$300M up front, ~$740M as development, regulatory and commercial milestones and is eligible to receive royalties of 20-25% on net sales If approved, the companies will co-develop ARO-AAT and co-commercialize it in the US, under 50/50 profit sharing structure. Additionally, Takeda… Read More »Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease

The COVID-19 Effect: How Pharma Can Adapt to the Evolving Patient Experience

  • by

Patient experiences are evolving. How can pharma keep up?By listening to the people who are navigating this new landscape everyday. Integrating personal experiences and patient-reported data, this one-day virtual event features real-time conversations between people living with chronic conditions and Health Union industry experts. Tune in to any… Read More »The COVID-19 Effect: How Pharma Can Adapt to the Evolving Patient Experience

Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma

  • by

Shots:   Pfizer to sponsor & conduct P-Ib/II study evaluating the safety, tolerability, and preliminary efficacy of dual regimen and will assume costs of study & other expenses related to IP rights.  The companies will form a joint development committee to manage clinical study which is… Read More »Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma

KOL Validation

  • by

A significant proportion of the clients we work with know that KOLs well. They also recognise that this in itself is the problem!   When you have been in a therapy area for a while and have done your KOL identification and KOL mapping previously,… Read More »KOL Validation

Anthem Expands Relationship with doc.ai to Power Digital Health Offerings

  • by

What You Should Know: – Anthem extends the use of doc.ai’s platform and portfolio of privacy-first technologies and artificial intelligence software services to drive the personalization of Anthem’s digital assets and create improved value for users. – doc.ai’s product offerings are deployed on its cloud-agnostic… Read More »Anthem Expands Relationship with doc.ai to Power Digital Health Offerings

Are there any pharma companies that offer 100% tuition reimbursement if one pursues part-time school while working?

  • by

Follow-up question: – Any pharmas that encourage joint working-PhD programs that aren’t insanely competitive/impossible to get into? I currently work at Pfizer, they offer $10k tuition reimbursement per year. For me, this means 2 master’s classes per year… which = 5 years for my master’s.… Read More »Are there any pharma companies that offer 100% tuition reimbursement if one pursues part-time school while working?